Medicolegal issues surrounding devices and mesh for surgical treatment of prolapse and incontinence. [Review]

MedStar author(s):
Citation: Clinical Obstetrics & Gynecology. 56(2):221-8, 2013 Jun.PMID: 23563873Institution: MedStar Washington Hospital CenterDepartment: Obstetrics and Gynecology/Female Pelvic Medicine and Reconstructive SurgeryForm of publication: Journal ArticleMedline article type(s): Journal Article | ReviewSubject headings: *Informed Consent | *Pelvic Organ Prolapse/su [Surgery] | *Surgical Mesh | *Urinary Incontinence/su [Surgery] | Female | Gynecology/ed [Education] | Humans | Malpractice/lj [Legislation & Jurisprudence] | Postoperative Complications | Product Surveillance, Postmarketing | Prostheses and Implants/ae [Adverse Effects] | Risk Factors | Surgical Mesh/ae [Adverse Effects] | United StatesLocal holdings: Available online from MWHC library: March 1996 - present, Available in print through MWHC library: 1999 - March 2003ISSN:
  • 0009-9201
Abstract: Legal issues related to vaginal mesh devices for prolapse and incontinence include abnormal injury and inadequate informed consent. Although vaginal mesh devices are currently cleared through the 510(k) process, new developments at the US Food and Drug Administration requiring additional postmarket studies (522 studies) for transvaginal mesh for prolapse and mini-suburethral synthetic slings have been issued to ensure product safety and effectiveness. New initiatives including unique device identification numbers and the Pelvic Floor Disorders Registry have been developed to improve surveillance throughout the total product/device life cycle.All authors: Iglesia CB, Nosti PADigital Object Identifier: Date added to catalog: 2013-12-24
Holdings
Item type Current library Collection Call number Status Date due Barcode
Journal Article MedStar Authors Catalog Article Available 23563873

Available online from MWHC library: March 1996 - present, Available in print through MWHC library: 1999 - March 2003

Legal issues related to vaginal mesh devices for prolapse and incontinence include abnormal injury and inadequate informed consent. Although vaginal mesh devices are currently cleared through the 510(k) process, new developments at the US Food and Drug Administration requiring additional postmarket studies (522 studies) for transvaginal mesh for prolapse and mini-suburethral synthetic slings have been issued to ensure product safety and effectiveness. New initiatives including unique device identification numbers and the Pelvic Floor Disorders Registry have been developed to improve surveillance throughout the total product/device life cycle.

Englishhttp://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&AN=00003081-201306000-00003&LSLINK=80&D=ovft

Powered by Koha